Therefore, further study is required to investigate whether cisplatin is able to enhance the secretion of TGF-β1, to induce mesenchymal-like phenotypic change, and to acquire cisplatin resistance in cancers where cisplatin is clinically available. Here, TGFB1 is linked to cancer.